HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents

Association honors AMA president-elect

Three elected to ASH executive committee

Research Center appoints director

Underutilized test may improve treatment decisions, outcomes in colon cancer

Neuro-oncologist receives NIH award

False-positive mammograms lead to greater prescription use for anxiety, depression

Cover Story

Efforts to address opioid epidemic must limit overuse without restricting access for cancer pain control

Editorial

Tobacco, alcohol and cancer: Not always black and white

John Sweetenham, MD

FDA News

Pembrolizumab approved for certain gastric cancers

Letermovir approved to prevent cytomegalovirus following HSCT

Elacestrant receives fast track designation for breast cancer subtype

Copanlisib approved for follicular lymphoma

ATA230 receives orphan drug designation for cytomegalovirus

PCM-075 receives orphan drug designation for AML

LN-144 receives fast track designation for advanced melanoma

Complete blood cell count test cleared with broad access

Acalabrutinib receives accelerated approval for mantle cell lymphoma

In the Journals

Comprehensive cancer survivorship services lacking in primary care

Cancer drug revenue substantially higher than R&D spending

In the Journals Plus

Researchers identify biomarkers for CAR T-cell therapy neurotoxicity

Most patients with cancer curious about marijuana use

Highly educated patients with acute myeloid leukemia show better survival in a universal health system

Gene profile may predict risk for stroke in sickle cell anemia

Perioperative interruption of direct oral anticoagulants safe, effective

Proton beam therapy shows promise for non-small cell lung cancer

Pembrolizumab superior to ipilimumab in advanced melanoma

Cerebrospinal fluid lymphoblasts at diagnosis impact prognosis in B-cell acute lymphoblastic leukemia

Surgery-based regimen improves survival in malignant pleural mesothelioma

Liquid biopsy offers option for EGFR testing without lung tumor tissue

HER-2 mutation found in advanced lung cancer

Midostaurin extends survival in acute myeloid leukemia with FLT3 mutation

Men with prostate cancer willing to pay more for advanced biopsies

Survivors of childhood cancer experience differences in psychosexual development

Clonal evolution predicts myelodysplastic syndrome progression

Colorectal cancer rates rising dramatically in young adults

Consolidation with arsenic trioxide effective for pediatric acute promyelocytic leukemia

CDC: Most cancers associated with obesity, overweight on the rise

ASCO: Even light alcohol use increases risk for cancer

BRAF V600E worsens outcomes in pediatric low-grade gliomas

Breast cancer subtype does not predict response to radiotherapy

Failed study shows need for esophageal cancer biomarkers

Formula predicts survival among adults with graft-versus-host disease

Adapted blood test predicts risk for anemia following malaria treatment

Daratumumab regimen shows promise in relapsed, refractory multiple myeloma

Early prostate cancer survival similar after radical prostatectomy, observation

Meeting News

Proposed tumor classification criteria appears accurate for non-small cell lung cancer

Rh-Endostatin in perioperative period improves osteosarcoma outcomes

Larotrectinib enables children with sarcoma to proceed to surgery

Surveillance, ablation important for management of small renal masses

Sarcoma coding often inaccurate

VEGF inhibitors may augment immunotherapy efficacy for first-line renal cell carcinoma

Ideal treatment for older adults with metastatic renal cell carcinoma remains unclear

Lay navigators improve quality of cancer care, reduce costs

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

Axitinib-pembrolizumab combination shows promise in advanced alveolar soft part sarcoma

Free texting service keeps patients’ families updated during cancer surgeries

Pembrolizumab doubles median OS for metastatic NSCLC

Nivolumab active in metastatic non-clear cell renal cell carcinoma

Pretreatment neutrophil-to-lymphocyte ratio predicts outcomes in metastatic renal cell carcinoma

Point/Counter

Should all patients with cancer undergo an addiction risk assessment prior to receiving opioids?

Advertisement
Advertisement